Baidu
map

诺华Afinitor获欧盟批准治疗非功能性胃肠道和肺部神经内分泌肿瘤(NET)

2016-06-05 佚名 生物谷Bioon.com

瑞士制药巨头诺华(Novartis)抗癌药Afinitor(everolimus,依维莫司,片剂)近日在欧盟监管方面传来喜讯。欧盟委员会批准Afinitor的新适应症,用于起源于胃肠道(gastrointestinal,GI)或肺部(lung)的不可切除性、局部晚期或转移性、进展性、分化良好型(1级或2级)非功能性神经内分泌肿瘤(neuroendocrine tumor,NET)成人患者的治疗

瑞士制药巨头诺华(Novartis)抗癌药Afinitor(everolimus,依维莫司,片剂)近日在欧盟监管方面传来喜讯。欧盟委员会批准Afinitor的新适应症,用于起源于胃肠道(gastrointestinal,GI)或肺部(lung)的不可切除性、局部晚期或转移性、进展性、分化良好型(1级或2级)非功能性神经内分泌肿瘤(neuroendocrine tumor,NET)成人患者的治疗。

这是欧盟28个成员国首个获批的用于治疗肺部非功能性神经内分泌肿瘤的药物,也是为数不多的用于治疗胃肠道非功能性神经内分泌肿瘤的药物之一。FDA已于今年2月批准Afinitor相同的适应症,目前Afinitor在美国可用于3类最常见的晚期NET的治疗。值得一提的是,在非功能性NET治疗领域,Afinitor是美国首个获批治疗晚期进展性非功能性肺部NET的药物,同时也是美国首个获批的晚期进展性非功能性胃肠道(GI)NET的口服治疗药物。

神经内分泌肿瘤(NET)是一种罕见的癌症类型,起源于遍布全身的神经内分泌细胞。NET最常见于胃肠道、肺部、胰腺。NET可被定义为功能性NET和非功能性NET。功能性NET是以激素和其他物质分泌过多引起的症状为特征。非功能性NET则是以可由肿瘤生长引起的症状为特征,例如肠胃道NET特征包括肠梗阻、疼痛及出血,肺部NET特征包括哮喘、慢性阻塞性肺病及肺炎。今年4月底,欧洲药品管理局(EMA)人用医药产品委员会(CHMP)支持批准Afinitor用于治疗该适应症,基于关键性III期RADIANT-4研究的疗效和安全性数据。临床试验结果表明,与安慰剂相比,Afinitor使该适应症的疾病进展风险显着降低52%,患者的无进展生存期(PFS)显着延长了7.1个月。

Afinitor已获全球99个国家(包括美国和欧盟)批准用于局部晚期、转移性、不可切除性、进展性、胰腺起源NET的治疗。此外,Afinitor已获全球超过120个国家批准治疗肾细胞癌,并且已在全球102个国家(包括美国和欧盟)获得批准,联合依西美坦(exemestane)用于之前已接受过内分泌治疗的HR+/HER2-乳腺癌。尽管Afinitor在众多国家收获了许多适应症,但仍面临许多激烈的竞争,如百时美的免疫检查点抑制剂Opdivo和Exelixis的Cometriq等。目前诺华仍在许多肿瘤中进行Afinitor的临床试验,以期获得更多的适应症。

原始出处:New approval for Novartis' Afinitor

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1953693, encodeId=fd35195369365, content=<a href='/topic/show?id=9bdbe41946e' target=_blank style='color:#2F92EE;'>#神经内分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74194, encryptionId=9bdbe41946e, topicName=神经内分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sat Jun 11 06:17:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682240, encodeId=fc8c168224013, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sat Feb 25 00:17:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733781, encodeId=c27e1e3378130, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Sep 29 10:17:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763463, encodeId=f36c1e634634f, content=<a href='/topic/show?id=3fc83035361' target=_blank style='color:#2F92EE;'>#内分泌肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30353, encryptionId=3fc83035361, topicName=内分泌肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=763a37536718, createdName=1249898am27暂无昵称, createdTime=Wed Jan 04 06:17:00 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915402, encodeId=6895191540210, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Mar 02 18:17:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282661, encodeId=457d12826611a, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346205, encodeId=e8d11346205c2, content=<a href='/topic/show?id=339e8332035' target=_blank style='color:#2F92EE;'>#胃肠道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83320, encryptionId=339e8332035, topicName=胃肠道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589963, encodeId=a9c31589963dd, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88861, encodeId=fcec88861b1, content=太多的东西值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20751724934, createdName=QQ76174b26, createdTime=Tue Jun 07 00:42:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88724, encodeId=549f88e249f, content=这个很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 06:45:00 CST 2016, time=2016-06-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1953693, encodeId=fd35195369365, content=<a href='/topic/show?id=9bdbe41946e' target=_blank style='color:#2F92EE;'>#神经内分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74194, encryptionId=9bdbe41946e, topicName=神经内分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sat Jun 11 06:17:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682240, encodeId=fc8c168224013, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sat Feb 25 00:17:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733781, encodeId=c27e1e3378130, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Sep 29 10:17:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763463, encodeId=f36c1e634634f, content=<a href='/topic/show?id=3fc83035361' target=_blank style='color:#2F92EE;'>#内分泌肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30353, encryptionId=3fc83035361, topicName=内分泌肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=763a37536718, createdName=1249898am27暂无昵称, createdTime=Wed Jan 04 06:17:00 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915402, encodeId=6895191540210, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Mar 02 18:17:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282661, encodeId=457d12826611a, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346205, encodeId=e8d11346205c2, content=<a href='/topic/show?id=339e8332035' target=_blank style='color:#2F92EE;'>#胃肠道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83320, encryptionId=339e8332035, topicName=胃肠道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589963, encodeId=a9c31589963dd, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88861, encodeId=fcec88861b1, content=太多的东西值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20751724934, createdName=QQ76174b26, createdTime=Tue Jun 07 00:42:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88724, encodeId=549f88e249f, content=这个很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 06:45:00 CST 2016, time=2016-06-06, status=1, ipAttribution=)]
    2017-02-25 gwc392
  3. [GetPortalCommentsPageByObjectIdResponse(id=1953693, encodeId=fd35195369365, content=<a href='/topic/show?id=9bdbe41946e' target=_blank style='color:#2F92EE;'>#神经内分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74194, encryptionId=9bdbe41946e, topicName=神经内分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sat Jun 11 06:17:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682240, encodeId=fc8c168224013, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sat Feb 25 00:17:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733781, encodeId=c27e1e3378130, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Sep 29 10:17:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763463, encodeId=f36c1e634634f, content=<a href='/topic/show?id=3fc83035361' target=_blank style='color:#2F92EE;'>#内分泌肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30353, encryptionId=3fc83035361, topicName=内分泌肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=763a37536718, createdName=1249898am27暂无昵称, createdTime=Wed Jan 04 06:17:00 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915402, encodeId=6895191540210, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Mar 02 18:17:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282661, encodeId=457d12826611a, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346205, encodeId=e8d11346205c2, content=<a href='/topic/show?id=339e8332035' target=_blank style='color:#2F92EE;'>#胃肠道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83320, encryptionId=339e8332035, topicName=胃肠道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589963, encodeId=a9c31589963dd, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88861, encodeId=fcec88861b1, content=太多的东西值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20751724934, createdName=QQ76174b26, createdTime=Tue Jun 07 00:42:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88724, encodeId=549f88e249f, content=这个很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 06:45:00 CST 2016, time=2016-06-06, status=1, ipAttribution=)]
    2016-09-29 仁者大医
  4. [GetPortalCommentsPageByObjectIdResponse(id=1953693, encodeId=fd35195369365, content=<a href='/topic/show?id=9bdbe41946e' target=_blank style='color:#2F92EE;'>#神经内分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74194, encryptionId=9bdbe41946e, topicName=神经内分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sat Jun 11 06:17:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682240, encodeId=fc8c168224013, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sat Feb 25 00:17:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733781, encodeId=c27e1e3378130, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Sep 29 10:17:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763463, encodeId=f36c1e634634f, content=<a href='/topic/show?id=3fc83035361' target=_blank style='color:#2F92EE;'>#内分泌肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30353, encryptionId=3fc83035361, topicName=内分泌肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=763a37536718, createdName=1249898am27暂无昵称, createdTime=Wed Jan 04 06:17:00 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915402, encodeId=6895191540210, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Mar 02 18:17:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282661, encodeId=457d12826611a, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346205, encodeId=e8d11346205c2, content=<a href='/topic/show?id=339e8332035' target=_blank style='color:#2F92EE;'>#胃肠道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83320, encryptionId=339e8332035, topicName=胃肠道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589963, encodeId=a9c31589963dd, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88861, encodeId=fcec88861b1, content=太多的东西值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20751724934, createdName=QQ76174b26, createdTime=Tue Jun 07 00:42:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88724, encodeId=549f88e249f, content=这个很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 06:45:00 CST 2016, time=2016-06-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1953693, encodeId=fd35195369365, content=<a href='/topic/show?id=9bdbe41946e' target=_blank style='color:#2F92EE;'>#神经内分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74194, encryptionId=9bdbe41946e, topicName=神经内分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sat Jun 11 06:17:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682240, encodeId=fc8c168224013, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sat Feb 25 00:17:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733781, encodeId=c27e1e3378130, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Sep 29 10:17:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763463, encodeId=f36c1e634634f, content=<a href='/topic/show?id=3fc83035361' target=_blank style='color:#2F92EE;'>#内分泌肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30353, encryptionId=3fc83035361, topicName=内分泌肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=763a37536718, createdName=1249898am27暂无昵称, createdTime=Wed Jan 04 06:17:00 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915402, encodeId=6895191540210, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Mar 02 18:17:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282661, encodeId=457d12826611a, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346205, encodeId=e8d11346205c2, content=<a href='/topic/show?id=339e8332035' target=_blank style='color:#2F92EE;'>#胃肠道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83320, encryptionId=339e8332035, topicName=胃肠道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589963, encodeId=a9c31589963dd, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88861, encodeId=fcec88861b1, content=太多的东西值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20751724934, createdName=QQ76174b26, createdTime=Tue Jun 07 00:42:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88724, encodeId=549f88e249f, content=这个很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 06:45:00 CST 2016, time=2016-06-06, status=1, ipAttribution=)]
    2017-03-02 xlxchina
  6. [GetPortalCommentsPageByObjectIdResponse(id=1953693, encodeId=fd35195369365, content=<a href='/topic/show?id=9bdbe41946e' target=_blank style='color:#2F92EE;'>#神经内分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74194, encryptionId=9bdbe41946e, topicName=神经内分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sat Jun 11 06:17:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682240, encodeId=fc8c168224013, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sat Feb 25 00:17:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733781, encodeId=c27e1e3378130, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Sep 29 10:17:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763463, encodeId=f36c1e634634f, content=<a href='/topic/show?id=3fc83035361' target=_blank style='color:#2F92EE;'>#内分泌肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30353, encryptionId=3fc83035361, topicName=内分泌肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=763a37536718, createdName=1249898am27暂无昵称, createdTime=Wed Jan 04 06:17:00 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915402, encodeId=6895191540210, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Mar 02 18:17:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282661, encodeId=457d12826611a, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346205, encodeId=e8d11346205c2, content=<a href='/topic/show?id=339e8332035' target=_blank style='color:#2F92EE;'>#胃肠道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83320, encryptionId=339e8332035, topicName=胃肠道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589963, encodeId=a9c31589963dd, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88861, encodeId=fcec88861b1, content=太多的东西值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20751724934, createdName=QQ76174b26, createdTime=Tue Jun 07 00:42:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88724, encodeId=549f88e249f, content=这个很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 06:45:00 CST 2016, time=2016-06-06, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1953693, encodeId=fd35195369365, content=<a href='/topic/show?id=9bdbe41946e' target=_blank style='color:#2F92EE;'>#神经内分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74194, encryptionId=9bdbe41946e, topicName=神经内分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sat Jun 11 06:17:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682240, encodeId=fc8c168224013, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sat Feb 25 00:17:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733781, encodeId=c27e1e3378130, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Sep 29 10:17:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763463, encodeId=f36c1e634634f, content=<a href='/topic/show?id=3fc83035361' target=_blank style='color:#2F92EE;'>#内分泌肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30353, encryptionId=3fc83035361, topicName=内分泌肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=763a37536718, createdName=1249898am27暂无昵称, createdTime=Wed Jan 04 06:17:00 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915402, encodeId=6895191540210, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Mar 02 18:17:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282661, encodeId=457d12826611a, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346205, encodeId=e8d11346205c2, content=<a href='/topic/show?id=339e8332035' target=_blank style='color:#2F92EE;'>#胃肠道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83320, encryptionId=339e8332035, topicName=胃肠道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589963, encodeId=a9c31589963dd, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88861, encodeId=fcec88861b1, content=太多的东西值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20751724934, createdName=QQ76174b26, createdTime=Tue Jun 07 00:42:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88724, encodeId=549f88e249f, content=这个很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 06:45:00 CST 2016, time=2016-06-06, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1953693, encodeId=fd35195369365, content=<a href='/topic/show?id=9bdbe41946e' target=_blank style='color:#2F92EE;'>#神经内分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74194, encryptionId=9bdbe41946e, topicName=神经内分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sat Jun 11 06:17:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682240, encodeId=fc8c168224013, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sat Feb 25 00:17:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733781, encodeId=c27e1e3378130, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Sep 29 10:17:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763463, encodeId=f36c1e634634f, content=<a href='/topic/show?id=3fc83035361' target=_blank style='color:#2F92EE;'>#内分泌肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30353, encryptionId=3fc83035361, topicName=内分泌肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=763a37536718, createdName=1249898am27暂无昵称, createdTime=Wed Jan 04 06:17:00 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915402, encodeId=6895191540210, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Mar 02 18:17:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282661, encodeId=457d12826611a, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346205, encodeId=e8d11346205c2, content=<a href='/topic/show?id=339e8332035' target=_blank style='color:#2F92EE;'>#胃肠道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83320, encryptionId=339e8332035, topicName=胃肠道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589963, encodeId=a9c31589963dd, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88861, encodeId=fcec88861b1, content=太多的东西值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20751724934, createdName=QQ76174b26, createdTime=Tue Jun 07 00:42:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88724, encodeId=549f88e249f, content=这个很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 06:45:00 CST 2016, time=2016-06-06, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1953693, encodeId=fd35195369365, content=<a href='/topic/show?id=9bdbe41946e' target=_blank style='color:#2F92EE;'>#神经内分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74194, encryptionId=9bdbe41946e, topicName=神经内分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sat Jun 11 06:17:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682240, encodeId=fc8c168224013, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sat Feb 25 00:17:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733781, encodeId=c27e1e3378130, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Sep 29 10:17:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763463, encodeId=f36c1e634634f, content=<a href='/topic/show?id=3fc83035361' target=_blank style='color:#2F92EE;'>#内分泌肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30353, encryptionId=3fc83035361, topicName=内分泌肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=763a37536718, createdName=1249898am27暂无昵称, createdTime=Wed Jan 04 06:17:00 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915402, encodeId=6895191540210, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Mar 02 18:17:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282661, encodeId=457d12826611a, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346205, encodeId=e8d11346205c2, content=<a href='/topic/show?id=339e8332035' target=_blank style='color:#2F92EE;'>#胃肠道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83320, encryptionId=339e8332035, topicName=胃肠道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589963, encodeId=a9c31589963dd, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88861, encodeId=fcec88861b1, content=太多的东西值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20751724934, createdName=QQ76174b26, createdTime=Tue Jun 07 00:42:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88724, encodeId=549f88e249f, content=这个很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 06:45:00 CST 2016, time=2016-06-06, status=1, ipAttribution=)]
    2016-06-07 QQ76174b26

    太多的东西值得学习

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1953693, encodeId=fd35195369365, content=<a href='/topic/show?id=9bdbe41946e' target=_blank style='color:#2F92EE;'>#神经内分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74194, encryptionId=9bdbe41946e, topicName=神经内分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sat Jun 11 06:17:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682240, encodeId=fc8c168224013, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sat Feb 25 00:17:00 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733781, encodeId=c27e1e3378130, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Sep 29 10:17:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763463, encodeId=f36c1e634634f, content=<a href='/topic/show?id=3fc83035361' target=_blank style='color:#2F92EE;'>#内分泌肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30353, encryptionId=3fc83035361, topicName=内分泌肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=763a37536718, createdName=1249898am27暂无昵称, createdTime=Wed Jan 04 06:17:00 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915402, encodeId=6895191540210, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Mar 02 18:17:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282661, encodeId=457d12826611a, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346205, encodeId=e8d11346205c2, content=<a href='/topic/show?id=339e8332035' target=_blank style='color:#2F92EE;'>#胃肠道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83320, encryptionId=339e8332035, topicName=胃肠道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589963, encodeId=a9c31589963dd, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Tue Jun 07 07:17:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88861, encodeId=fcec88861b1, content=太多的东西值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20751724934, createdName=QQ76174b26, createdTime=Tue Jun 07 00:42:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88724, encodeId=549f88e249f, content=这个很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 06 06:45:00 CST 2016, time=2016-06-06, status=1, ipAttribution=)]
    2016-06-06 milkshark

    这个很好

    0

相关资讯

诺华重磅药物Jakavi欧盟收获新适应症:真性红细胞增多症(PV)

诺华(Novartis)在欧盟监管方面近日传来大好消息,该公司研发的口服JAK激酶抑制剂Jakavi(ruxolitinib)在欧盟收获了新适应症——用于对羟基脲(hydroxyurea)有抵抗或不耐受的真性红细胞增多症(PV,简称“真红”)成人患者的治疗,该药也成为欧盟批准的首个PV靶向治疗药物。此前,Jakavi已于2012年8月获欧盟批准用于骨纤维化的治疗。在美国,FDA分别于2011年

心脏病重大里程碑!诺华心衰药Entresto(LCZ696)获FDA批准!

瑞士制药巨头诺华(Novartis)监管方面收获重大里程碑,该公司备受瞩目的慢性心衰药物Entresto(前称LCZ696)近日提前6周获得FDA批准,用于射血分数降低的心力衰竭(heart failure)患者,降低心血管死亡和心衰住院风险。Entresto是一种首创新药,以多种方式作用于心脏的神经内分泌系统,该药是过去25年内心衰治疗领域的一个伟大突破,有望成功动摇过去10年未被修改的心衰治疗

抗癌药物格列卫专利到期 患者使用伊马替尼5年可省10万美元

美国约翰霍普金斯大学的科学家们表示,抗癌药物格列卫(Gleevac)如果被伊马替尼(imatinib)取代,5年可为患者节省10万美元,可为拥有100位患者的保险公司节省900多万美元。 据合众社报道,随着诺华制药的专利药物格列卫专利期满,伊马替尼投放市场时,价格仅为格列卫的十分之一。 格列卫是一种酪氨酸激酶抑制剂,可用于治疗慢性骨髓性白血病,可以帮助5年内不复发的患者存活下去。在此期间,

诺华突破性药物bimagrumab临床后期研究遭遇滑铁卢

诺华公司最近表示,公司开发的用于治疗散发性包涵体肌炎新药bimagrumab(BYM338)在一项最新的临床IIb/III期研究中未能达到首要终点而宣告失败。这一结果对公司研发部门造成重创,甚至有人认为这是诺华公司研发部门近年来遭遇的最大失败。 对于BYM338,诺华公司一直寄予厚望。此前公司已经获得了美国FDA授予的突破性药物认证。公司还希望将这种药物拓展到包括COPD在内的多种疾病治疗中去。

药不提当年勇:诺华心衰药物Entresto拟按真实世界有效性收费

近日诺华宣布和两个主要健康保险公司Cigna和Aetna签署其心衰药物Entresto的支付协议。诺华将提供一个基线折扣,然后根据Entresto在真实世界的表现增加(如果未达到预期疗效)或降低(超过预期疗效)这个折扣。但是双方并未公布具体内容,比如预期疗效、折扣具体数目等。在政府控制药价比较严的欧洲,如英国的NICE,经常和药厂达成这类协议。但这将是美国市场第一个主动按质论价的新药。在此之前

诺华有望迎来美国上市的第一个生物仿制药

作为安进肿瘤生物药Neupogen的生物仿制药,诺华Zarzio近日获得了FDA官员的推荐,同时该药也有望成为美国第一个上市的生物仿制药。 根据2010年颁布的患者保护与平价医疗法案,只要具有足够的价格优势,研发的生物仿制药与原研药即使不百分百等同也可以获批。从2006年开始,欧洲的生物仿制药就逐渐获批,而美国由于缺乏相关的规章制度,生物仿制药市场发展仍相对滞后。 生物药在癌症和其他免疫疾病的

Baidu
map
Baidu
map
Baidu
map